Christopher Haqq, EVP, R&D & Chief Scientific Of at Atara Biotherapeutics, Inc. (ATRA), sold 35,554 shares at $39.76 ($1.4M) on 2018-03-26, disclosed to the SEC on 2018-03-27.
Open-market sale of $1.4M ATRA by EVP, R&D & Chief Scientific Of. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.76 | 17,227 | $685K | 48.4% |
| 2 | $39.76 | 17,227 | $685K | 48.4% |
| 3 | $40.29 | 1,100 | $44K | 3.1% |
| Total | $39.78 avg | 35,554 | $1.4M | 100% |
| Filing → |
| ATRA | SELL | 2019-02-08 | $956K | — | Filing → |
| ATRA | SELL | 2018-11-15 | $26K | — | Filing → |
| ATRA | SELL | 2018-09-27 | $582K | — | Filing → |